Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma
June 4, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for pe...
Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy
May 28, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present...
Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials
February 25, 2019, Melbourne, Australia – Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advan...
February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy...
2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research Commercialisation Fund (MRCF) to complete the ongoing Phase 1 clinical trial, AVX001, and progress Phase 2 plans for its novel treatment of pean...
